Clinical Trial

Patient-Reported AutoImmunity Secondary to Cancer immunothErapy

Study acronym: PRAISE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a real life observational longitudinal study aiming to identify autoimmune manifestations in patients treated with "checkpoint inhibitors" in mono or combo therapy in real life. The study is based on patients reported experience validated by physician, recruited in cancer centers in France with another data collection from a French healthcare data claims database and a biological collection.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-02-19; most recent amendment 2025-03-10.
Status change: Recruiting → Active, Not Recruiting 2025-03-10
Status change: Not Yet Recruiting → Recruiting 2020-01-22
Trial Details
NCT Number NCT03849131
Lead Sponsor University Hospital, Strasbourg, France
Conditions Opportunistic Autoimmune Diseases
Enrollment 905 participants
Start Date 2019-11-29
Primary Completion 2025-06 (estimated)
Study Completion 2025-06 (estimated)
Updated on ClinicalTrials.gov 2025-03-12